Jazz Pharmaceuticals Plc (JAZZ) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access JAZZ Annual Cash Flow →
Quarterly cash flow trends provide additional context on Jazz Pharmaceuticals Plc's liquidity and ability to support ongoing operations and capital needs.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income485.90
Depreciation & amortization18.20
Amortization of Other Assets342.30
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories107.70
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Other Assets122.80
Share-based Compensation147.80
Proceeds from Equity Method Investment, Dividends or Distributions-0.10
Gains (Losses) on Extinguishment of Debt2.40
Increase Decrease In Deferred Rent-
Fair Value Inventory Step Up Adjustment-
Provision For Losses On Accounts Receivable And Inventory14.20
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Increase Decrease In Operating Lease Assets-
Inventory Step Up Value Adjustment37.50
Increase Decrease In Contract With Customer Liability-
Noncash Interest Expense4.70
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable51.40
Increase (Decrease) in Accounts Payable7.10
Increase (Decrease) in Accrued Liabilities0.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-56.80
Other Working Capital-11.60
Other Noncash Income (Expense)-1.50
Other net0.00
Payments for (Proceeds from) Other Operating Activities-392.30
Discontinued operations0.00
Net Cash flow from Operating Activities823.90
Investing Activities
Capital Expenditures-115.00
Sale of Capital Items200.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities0.00
Real Estate Investments0.00
Payments To Acquire Product Rights-
Paymentsto Acquire In Process Research and Development Other Than Through Business Combination-
Payment To Acquire Assets Net Of Cash Acquired-
Payments To Acquire In Process Research And Development Other Than Through Business Combination-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments470.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Assets, Investing Activities0.00
Payments to Acquire Additional Interest in Subsidiaries0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-77.00
Discontinued operations0.00
Net Cash Flow from Investing Activities478.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1,015.50
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock55.60
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-113.10
Other net0.00
Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants-
Proceeds From Stock Options And Warrants Exercises-
Proceeds From Issuance Of Term Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1,073.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow908.90
Total Cash Flow227.90
4 historic quarters locked

Sign in to unlock the full Jazz Pharmaceuticals Plc cash flow history.

About Jazz Pharmaceuticals Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001232524-26-000045

Figures are derived from filed reports and may be restated. Historical data is subject to revision.